Reni J. Benjamin
Stock Analyst at Citizens
(1.88)
# 3,226
Out of 5,143 analysts
17
Total ratings
33.33%
Success rate
-0.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Initiates: Market Outperform | $10 | $2.80 | +257.14% | 2 | Feb 23, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $16.12 | +148.14% | 4 | Jan 30, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Market Outperform | $31 | $16.24 | +90.89% | 1 | Jan 29, 2026 | |
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $23.63 | +35.42% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $369.00 | +7.32% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $4.23 | +89.13% | 1 | Oct 30, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $8.38 | +186.40% | 2 | Oct 20, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $79.50 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $0.66 | +353.45% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $2.86 | +4.90% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.19 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $5.62 | +77.94% | 1 | Aug 12, 2025 |
Immutep
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $2.80
Upside: +257.14%
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $16.12
Upside: +148.14%
Bicara Therapeutics
Jan 29, 2026
Initiates: Market Outperform
Price Target: $31
Current: $16.24
Upside: +90.89%
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $23.63
Upside: +35.42%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $369.00
Upside: +7.32%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $4.23
Upside: +89.13%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $8.38
Upside: +186.40%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $79.50
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.66
Upside: +353.45%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $2.86
Upside: +4.90%
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.19
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $5.62
Upside: +77.94%